IP Library Granted Patent US 7,052,875
Granted Patent B1
US 7,052,875 · App. 09/701,013 · Granted May 30, 2006

Stable gene preparations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,052,875
App. No.
09/701,013
Granted
May 30, 2006
Kind
B1
Abstract

The invention is directed to the retention of the stability of formulations useful for a gene therapy during the preparation and preservation. In the invention, at least one saccharide and/or at least one non-hydrophobic amino acid and/or at least one organic acid having two or more carboxyl groups except amino acids, or a collagen or a gelatin and at least one amino acid are added to a gene formulation.

Claims (12)

1. A method for stabilizing a closed circular DNA molecule in a formulation, comprising:

adding citric acid or tartaric acid, or a salt thereof, to an aqueous solution of the closed circular DNA and atelocollagen, and

lyophilizing the solution.

2. The method of claim 1 , wherein the aqueous solution of the closed circular DNA further comprises a cationic lipid, a cationic polymer or a hydrophobic polymer.

3. The method of claim 2 , wherein the amount of citric acid or tartaric acid is not less than 1% w/v of the aqueous solution of the closed circular DNA.

4. The method of claim 1 , wherein the amount of citric acid or tartaric acid is not less than 1% w/v of the aqueous solution of the closed circular DNA.

5. A method for stabilizing a closed circular DNA molecule in a formulation, comprising:

adding atelocollagen to an aqueous solution of the closed circular DNA and citric acid or tartaric acid or both citric acid and tartaric acid, or a salt thereof, and

lyophilizing the solution.

6. The method of claim 5 , wherein the aqueous solution of the closed circular DNA further comprises a cationic lipid, a cationic polymer or a hydrophobic polymer.

7. The method of claim 6 , wherein the amount of citric acid or tartaric acid is not less than 1% w/v of the aqueous solution of the closed circular DNA.

8. The method of claim 5 , wherein the amount of citric acid or tartaric acid is not less than 1% w/v of the aqueous solution of the closed circular DNA.

Assignments (2)
MERGER Recorded Dec 16, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LTD.
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017089/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2001
From: TERADA, MASAAKI; OCHIYA, TAKAHIRO; SANO, AKIHIKO; HISADA, AKIHIKO; NAGAHARA, SHUNJI
To: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED; KOKEN CO., LTD.
Reel/Frame 011465/0757 →